Cheplapharm is booming: sales have tripled and new opportunities are in sight!

Cheplapharm is booming: sales have tripled and new opportunities are in sight!

Things are going haywire in Greifswald: The pharmaceutical company Cheplapharm has developed enormously in recent years and was able to increase its sales to a whopping 1.5 billion euros from 2019 to 2024. This is good news reported NDR. In addition to the impressive doubling of sales, Cheplapharm has purchased several products and thus built up a growing portfolio. This not only leads to an increase in sales, but also to more complex processes in the company.

Comprehensive measures are now planned for 2025. The optimization of internal processes and systems is necessary in order to master the challenges of an evolved corporate structure. The restructuring has already begun, but will be pushed further in the coming year. With these steps, Cheplapharm wants to take advantage of new market opportunities and consolidate its position as one of the most important employers in the region. The company currently employs 799 people, 550 of them in Greifswald, which means an increase of 14 employees compared to the previous year.

Powerful business numbers

But that's not all: in the first half of 2025, the company reported sales of 813.4 million euros, which corresponds to an increase of 12% compared to the same period last year. The EBITDA is also impressive: with 337.6 million euros and an EBITDA margin of 42%, Cheplapharm is one of the leading companies in the industry Cheplapharm Documentation shows.

The past 2024 financial year was particularly challenging for Cheplapharm, especially the second half of the year. Nevertheless, the company is heading into 2025 with a transformation program that aims to improve processes and further optimize operational business. A renowned consulting company was even brought on board for this purpose, ushering in a new era for Cheplapharm.

Global challenges

The pharmaceutical industry not only faces opportunities, but also challenges. The globally networked industry, which exports more than 60 billion euros in pharmaceutical products from Germany abroad, is currently confronted with new customs policies. From August 2025, the US government plans to impose 15 percent tariffs on goods imported from the EU, including pharmaceuticals. This could have relevant implications for companies like Cheplapharm, which are heavily involved in international business Statista seconded.

All of these developments show that Cheplapharm is not only an important player in the Vorpommern-Greifswald region, but also competes with the major players in the industry on a global level. The future promises to be exciting, not only for the company itself, but also for its employees and the region.